Novocure (NVCR) reported $655M in revenue for fiscal 2025, +8.3% year on year. That ranks #2046 by revenue among 2853 SEC filers and #196 in Healthcare. It posted a net loss of −$136M for the same year. Revenue has grown 25.8% a year on average since 2016 ($82.9M then). The fiscal 2025 balance sheet shows $804M in total assets, $93.5M in cash and $195M in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $655M | +8.3% | FY20252025-12-31 |
| Gross profitGrossProfit | $488M | +4.4% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$154M | +$16.7M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | −$136M | +$32.8M | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$49.0M | −$22.7M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $26.6M | −37.8% | FY20252025-12-31 |
| Total assetsAssets | $804M | −35.2% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $340M | −5.5% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $93.5M | −42.9% | FY20252025-12-31 |
| Long-term debtLongTermDebtNoncurrent | $195M | +100.5% | FY20252025-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $174M | −$71.1M | Open → |
| Q2 20262026-06-30 | $184M | −$15.7M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Novocure Ltd
- Ticker
- NVCR
- Exchange
- Nasdaq
- SIC classification
- Surgical & Medical Instruments & Apparatus (3841)
- Fiscal year end
- 12-31
- CIK
- 0001645113
Filings
- 10-QJul 23, 2026Open filing →
- 10-QApr 30, 2026Open filing →
- 10-KFeb 26, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| SNDLSNDL | $677M | −$11.3M |
| Ultragenyx PharmaceuticalRARE | $673M | −$575M |
| Cresco LabsCRLBF | $656M | −$135M |
| NovocureNVCR | $655M | −$136M |
| Axsome TherapeuticsAXSM | $638M | −$183M |
| TG TherapeuticsTGTX | $616M | $447M |
| Cadre HoldingsCDRE | $610M | $44.1M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Novocure — Key figures |url=https://companiesranked.com/en/company/novocure |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Novocure — Key figures. CompaniesRanked. https://companiesranked.com/en/company/novocureBibTeX
@misc{companiesranked-en-company-novocure-2026,
author = {{CompaniesRanked}},
title = {{Novocure — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/novocure}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-Q · 0001645113-26-000062 · July 23, 2026
{{cite web |title=Novocure — Key figures — 10-Q (0001645113-26-000062) |url=https://www.sec.gov/Archives/edgar/data/1645113/000164511326000062/nvcr-20260630.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-07-23}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.